BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma

Contributed by: Business Wire

Logo

Tags

Research

FDA

Clinical Trials

Biotechnology

General Health

Pharmaceutical

Health

Science

Oncology

Other Science

BRUKINSA Frontline Mantle Cell Lymphoma

More Like This

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts

BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia